Latest News & Updates
Breaking News
12 hours ago
Vaibhavi M.
Other trending news you may like to read
Roche Discontinues Emugrobart Development In SMA And FSHD After Efficacy Review, Myostatin Antibody Fails To Advance In Neuromuscular Trials
Roche discontinues emugrobart in SMA and FSHD after Phase II/III data show insufficient efficacy; safety profile intact; obesity trials unaffected, per Chugai.
Vaibhavi M.
HUTCHMED Initiates Phase III Trial Of HMPL-760 Combination Therapy In Diffuse Large B-Cell Lymphoma
HUTCHMED begins Phase III trial of HMPL-760 plus R-GemOx in relapsed/refractory DLBCL in China; first patient dosed March 20, 2026; ~240 patients to enroll.
Vaibhavi M.
Zydus Launches Semaglutide Injection With Reusable Pen To Improve Diabetes Care Access, Patent Expiry Opens Door For Affordable GLP-1 Therapy
Zydus Lifesciences launches semaglutide injection under brands SEMAGLYN, MASHEMA, and ALTERME in India with a reusable multi-dose pen, priced at approximately ₹2,200 per month.
Vaibhavi M.
Glenmark Launches Affordable Semaglutide GLIPIQⓇ To Expand Diabetes Care Access In India, Sets New Cost Benchmark For GLP-1 Therapy With Flexible Dosing Options
Glenmark Pharmaceuticals launches GLIPIQ (semaglutide) in India for Type 2 diabetes after CDSCO approval, with weekly costs from ₹325 and a patient support program called Sankalp.
Vaibhavi M.
